Pretransplant values of serum ferritin, albumin, and peripheral blood counts were previously suggested to provide prognostic information about hematopoietic cell transplantation (HCT) outcomes. Whether these "biomarkers" have prognostic value independent of each other and the HCT-comorbidity index (HCT-CI) is unknown. We analyzed data from 3917 allogeneic HCT recipients at multiple sites in the United States and Italy using multivariate models including each biomarker and the HCT-CI. Data from all sites were then randomly divided into a training set (n ¼ 2352) to develop weights for the relevant biomarkers to be added to the HCT-CI scores and a validation set (n ¼ 1407) to validate an augmented HCT-CI compared with the original index. Multivariate analysis with data from one site showed that ferritin, albumin, and plateletsdnot neutrophils or hemoglobindwere independently associated with increased nonrelapse mortality (NRM) and decreased overall survival. Findings were validated in data from the other sites. Subsequently, in a training set from all sites, ferritin >2500 mg/dL (hazard ratio [HR], 1.69); albumin 3 to 3.5 g/dL (HR, 1.61) and <3.0 g/dL (HR, 2.27); and platelets 50 to <100,000 (HR, 1.28), 20 to <50,000 (HR, 1.29), and <20,000 (HR, 1.55) were statistically significantly associated with NRM. Weights were assigned to these laboratory values following the same equation used to design the original index. In the validation set, the addition of the biomarkers to the original index to develop an augmented HCT-CI resulted in a statistically significant increase in a higher c-statistic estimate for prediction of NRM (P ¼ .0007). Ferritin, albumin, and platelet counts are important prognostic markers that further refine the discriminative power of the HCT-CI for transplant outcomes. Ó
INTRODUCTION
Development of an optimal model for predicting prognosis after hematopoietic stem cell transplantation (HCT) remains an active area of research. Certainly, disease and treatment characteristics play a large role. Additional contributions arise from the physical abilities of patients to tolerate allogeneic HCT. The HCT-comorbidity index (HCT-CI) was developed in 2005 to measure relationships between medical comorbidities and nonrelapse mortality (NRM) after HCT [1] . This index has now been validated in multiinstitutional studies [2] [3] [4] . The HCT-CI is being used to Biology of Blood and Marrow Transplantation j o u r n a l h o m e p a g e : w w w . b b m t . o r g counsel patients about prognosis and to risk-stratify patients in studies examining outcomes after HCT [5, 6] . Previously, the use of objective laboratory measures within the HCT-CI has improved its performance compared with the Charlson comorbidity index [7] . Whether the discriminative capacity of the HCT-CI could be further augmented by adding additional laboratory values is not known.
Previous studies have shown that a number of additional objective laboratory "biomarkers" are of interest if pre-HCT risk assessment is to be optimized. Serum albumin inversely correlates with age, smoking, obesity, and hypertension; serves as a marker of inflammatory status; and predicts cardiovascular mortality [8, 9] . Serum ferritin is an acute phase reactant, and elevated levels suggest iron overload, which has been linked to post-HCT infections, hepatic, and pulmonary complications [10] [11] [12] [13] . Finally, cytopenias, as represented by absolute neutrophil count (ANC), hemoglobin (Hgb), or platelet count, could indicate poor marrow function related to persistent malignancy or effects of prior treatment [14] [15] [16] .
Here, we analyzed the independent prognostic role of 5 readily available biomarkers (albumin, ferritin, ANC, Hgb, and platelet count) in a large group of patients treated with allogeneic HCT at multiple centers in the United States and Italy. We asked two main questions: (1) Which, if any, of these 5 biomarkers is independently associated with risks of NRM and OS? (2) Could we integrate the relevant biomarkers into the HCT-CI to improve its performance?
METHODS

Patients
We retrospectively collected data from 3917 patients who received allogeneic HCT at the Fred Hutchinson Cancer Research Center (FHCRC) (n ¼ 1789) and the Dana Farber Cancer Institute (DFCI) (n ¼ 716) in the United States and at Gruppo Italiano Trapianto di Midollo Osseo (GITMO) (n ¼ 1412), a network of institutions in Italy. The study was approved by the internal review boards of the FHCRC, DFCI, and the GITMO centers. Patients were included in the analysis if they received allogeneic HCT with either high-dose or reduced intensity/nonmyeloablative conditioning regimens, as previously defined [17] , and received either HLA-matched related or unrelated donor grafts. Informed consent was obtained from all patients at the time of transplantation in accordance with the Declaration of Helsinki.
Definitions
HCT-CI scores were calculated by investigators at each institution according to previously published criteria [1] . Physical function before HCT was assessed using Karnofsky performance status (KPS). Low-risk diseases included chronic myeloid leukemia in first chronic phase, acute leukemia in first complete remission, myelodysplasia-refractory anemia or refractory anemia with ringed sideroblasts, and nonmalignant hematologic diseases. High-risk diseases included all other diagnoses.
The values of ferritin, albumin, ANC, Hgb, and platelet count obtained closest to and up to day À10 before HCT were used in the analysis. Ferritin concentrations were evaluated in increments of 1000, 1000 to 2500, and !2500 mg/dL consistent with cutoffs used in prior studies [18] [19] [20] . Serum albumin concentrations were divided into 3 categories, !3.5, 3.0 to 3.5, and <3.0 g/dL, also similar to previous studies [21, 22] . ANC values were evaluated in increments of >1500, 1000 to 1500, 500 to 1000, and <500/mL. Hgb values were evaluated at cutoff values of >10, 9 to 10, and <9/mL. Platelet counts were evaluated in 4 increments: >100,000, 50,000 to 100,000, 20,000 to 50,000, and <20,000/mL.
Statistical Analysis
Overall survival (OS) was estimated by the Kaplan-Meier method. Cumulative incidence of NRM was estimated by standard methods, with relapse and progression treated as competing risks. Cox regression models were used to evaluate the association between each of the laboratory variables and risk of NRM, adjusting for HCT-CI score (0, 1, 2, 3, 4þ), donor type (related, unrelated), patient cytomegalovirus serology results (À, þ), regimen intensity (high-dose, reduced-intensity/nonmyeloablative), patient age (<50, !50 years), diagnosis category (myeloid versus others), relapse risk (low, high), and KPS. Analysis was stratified by institution. Missing information on any biomarker was included in the models as a separate variable.
To ensure that any notable associations between the biomarkers of interest and NRM were reproducible across institutions, we first assessed their effect in a data set from a single institution (FHCRC, n ¼ 1789). Biomarkers that showed statistically significant independent associations with risks of NRM in the FHCRC population were then assessed using similar statistical methods in a larger, more heterogeneous data set from the remaining 2 institutions (DFCI and GITMO, n ¼ 2128).
In order to develop and assign weights to biomarkers, patients from all centers were then randomly divided into 2 cohorts: 2352 (60%) patients were assigned to a training set; the remaining 40% were assigned to a validation set (n¼1565). Patients with missing albumin and platelet data were then excluded from the validation set (n¼158), with a final sample of 1407 patients contributing to the validation analysis. Integer weights for biomarkers were derived from Cox proportional hazards modeling applied to the training set, with NRM as the outcome of interest. Hazard ratios (HRs) for NRM were calculated for each biomarker value, controlling for the presence of all covariates described above, including HCT-CI scores, and were stratified by institution. Multivariate P values for each variable were based on adjustment for all other variables in the model. All P values were derived from likelihood ratio statistics and were 2-sided. The adjusted HRs were converted to integer weights according to our previously published criteria [1] . The augmented HCT-CI score for each patient was the sum of the score assigned to the HCT-CI plus that assigned to each biomarker value.
In the validation set, we compared the capabilities of the HCT-CI versus the augmented model to discriminate risks of NRM and overall mortality. Comparisons were done by computing c-statistic estimates [23] with the same interpretation of results as previously described [1] . The c-statistic was computed based on time-to-event data using the entire follow-up period. Standard errors for the c-statistic and differences between c-statistics for the original and augmented HCT-CI were evaluated in 50 bootstrap samples and then analyzed by paired t-tests.
RESULTS
Patient Characteristics
Forty-five percent of patients were !50 years of age. Approximately half of the patients received grafts from HLA-matched related donors, and the remainder received HLA-matched unrelated donor grafts. A slight majority of patients (58%) were considered to have high-risk disease. Fifty-four percent of patients received high-dose conditioning. The remaining 46% received either reduced-intensity or nonmyeloablative regimens. A significant number of patients Table 1 .
Associations between Individual Biomarkers and NRM and OS
To ensure reproducibility across institutions, we elected to perform an initial analysis within the FHCRC population (n ¼ 1758). In that multivariate model accounting for all 5 biomarkers, the HCT-CI, and other variables, only ferritin >1000 mg/dL (HR 1.98; P ¼ .0003) and >2500 mg/dL (HR 1.97; P ¼ .0005), albumin <3.5 g/dL (HR 1.63; P < .00001) and <3.0 g/dL (HR 1.73; P < .0001), and platelet counts <100,000/ mL (HR 1.65; P < .0001), <50,000/mL (HR 1.52; P < .0001), and <20,000/mL (HR 1.54; P < .008) remained independently associated with NRM. Hgb and ANC values did not have statistically significant associations with NRM in these models.
Results were then validated in a larger population of patients from DFCI and GITMO. In multivariate models, adjusted for the previously mentioned variables, ferritin >2500 and incremental decreases in albumin and platelets counts had statistically significant associations with both NRM and survival ( Table 2 ). Of note, HCT-CI scores (2, 3, and !4) also retained statistically significant associations with NRM and survival in the presence of the 3 biomarker values in both the initial FHCRC and combined DFCI/GITMO cohorts. Figure 1 shows the association between serum ferritin, serum albumin, and platelet count with NRM in the combined cohort, which includes all 3 institutions (n ¼ 3917). The entire cohort (n ¼ 3917) was then stratified into a training set (n ¼ 2352) and a validation set (n ¼ 1407). In the training set, albumin <3.5 g/dL and <3.0 g/dL; platelet counts <100,000, <50,000, and <20,000; and ferritin >2500 mg/dL had statistically significant associations with NRM ( Table 3) .
Incorporation of the Biomarker Values with the HCT-CI in an Augmented Model
Each of the 3 biomarker values, ferritin !2500 mg/dL, albumin 3.0 to <3.5 g/dL, and platelet counts <100,000, were subsequently assigned a weight of 1, whereas albumin <3.0 g/dL was assigned a weight of 2 following the same equation used to develop the HCT-CI (Table 4 ) [7] .
In the validation set, we confirmed that ferritin >2500 mg/dL, albumin <3.0 and 3.0 to <3.5 g/dL, and platelet counts <100,000 stratified cumulative incidences of NRM well (Figure 2 ). Weights were then assigned to each of the 3 biomarkers (ferritin, albumin, and platelet counts) and added to those of the HCT-CI to compute the augmented HCT-CI score for each patient. Although 41%, 32%, 20%, and 7% of patients had HCT-CI scores of 0, 1 to 2, 3 to 4, and !5, respectively, the corresponding percentages for augmented HCT-CI scores of 0, 1 to 2, 3 to 4, and !5 were 22%, 38%, 24%, and 16%, respectively (Figure 3 ). The augmented model had a higher c-statistic estimate (.61) for prediction of NRM compared with the HCT-CI alone (.58) when measured as a continuous variable. This difference was statistically significant (P ¼ .0007).
With the use of the augmented HCT-CI scores, patients were stratified into 4 risk groups of scores of 0, 1 to 2, 3 to 4, and !5 for rates of NRM and survival. In adjusted multivariate models, patients with scores of 1 to 2, 3 to 4, and !5 had HRs of 1.05 (95% confidence interval [CI], .9 to 1.3), 1.35 (95% CI, 1.1 to 1.7), and 2.13 (95% CI, 1.7 to 2.7), respectively, for NRM compared with those with score 0. For OS, the HRs were 1.13 (95% CI, .9 to 1.4), 1.53 (95% CI, 1.2 to 1.9), and 2.74 (95% CI, 2.2 to 3.5), respectively. Both associations were highly statistically significant with P < .0001 for both outcomes.
DISCUSSION
We elected to test the associations between 3 specific biomarkers (ferritin, albumin, and blood cell counts) with HCT outcomes because they have a track record of being associated with specific organ comorbidities and, as shown in previous studies, have the potential to influence post-HCT morbidity and mortality [16, 19, [24] [25] [26] [27] [28] [29] [30] [31] . There were 2 important findings. First, ferritin !2500 mg/dL, albumin 3 to 3.5 and <3 g/dL, and platelet counts < 100,000/mL were independently associated with increased risks of NRM and overall mortality after allogeneic HCT. This finding was confirmed in 2 distinct sensitivity analyses: 1 testing their performance characteristics in 2 independent center-specific (FHCRC versus DFCI/GITMO) cohorts and the other in 2 randomly selected training and validation sets for weight assignment. Second, we were able to demonstrate that the discriminative capacity of the HCT-CI could be improved by incorporating weights for multiple significant objective biomarkers. This was done by using data from a large groups of patients treated at multiple centers in 2 different continents to ensure reproducibility of results.
Understanding the biological basis of these associations is an important area of continuing investigation. Although multiple studies, in addition to ours, have shown a strong association between elevated pre-HCT ferritin and increased risk of NRM mortality [19, 20, 24, 26, 27, 32] after allogeneic HCT, the assertion that this relationship is solely due to the effects of chronic iron overload has been disputed [20, 29, [33] [34] [35] . One hypothesis is that high levels of ferritin, an acute phase reactant, may indicate the presence of inflammation and occult tissue injury. Low serum albumin, although frequently used as a marker of nutritional status or hepatic function, is also a well-recognized indicator of chronic inflammation. Despite this fact, ferritin and albumin have independent associations with NRM and OS in our analysis, suggesting their physiologic contribution to prognosis occurs through at least partially separate mechanisms. This interpretation is consistent with results of previous studies showing that adjustment for hypoalbuminemia did not attenuate the risk of NRM associated with high serum ferritin concentrations [19] . Other investigators have suggested that high ferritin levels may correlate with the effects of acute iron toxicity and that pre-HCT transfusion burden [30] or specific biomarkers measuring circulating free iron may serve as more reliable prognostic variables [20, 36] . Additional studies are needed to better characterize the physiologic basis of ferritin's prognostic impact because it could have significant implications for the incorporation of iron chelation as part of peri-HCT care [37, 38] .
Hypoalbuminemia before HCT may reflect poor nutritional status and poor hepatic synthetic function, even though the HCT-CI accounts for elevated serum bilirubin and transaminase concentrations. Supporting the inference that the effect of low albumin on outcome is dictated by its correlation with nutritional status are previous studies that show the importance of pre-HCT nutritional status to OS after HCT using more specific measurement tools such as body mass index, bioimpedance, and anthropometry [39] [40] [41] . As with ferritin, the prognostic value of serum albumin highlights a potential area of intervention (eg, aggressive nutritional supplementation pre-HCT) that could be targeted to improve outcome.
Peripheral blood count recovery before HCT is often used by physicians as a marker of poor marrow reserve after prior therapies. Thrombocytopenia, in particular, predicts OS after recovery from induction chemotherapy for acute myelogenous leukemia [16] and after HCT for myelodysplastic syndrome, independent of disease or cytogenetic risk [15] . Despite previous studies suggesting that pre-HCT neutropenia may lead to inferior outcome [28] , in our current larger analysis, low ANC was not associated with increased risk of NRM after adjusting for HCT-CI and other biomarkers. Pre-HCT Hgb also showed no association. These results may suggest that platelet count has a higher sensitivity to the severity of prior treatment or underlying persistent malignancy, both of which place patients at higher risk of nonrelapse death after HCT. Using a training-validation approach, we were able to assign scores to the 3 biomarkers and combine them with the HCT-CI scores in an augmented model. A statistically significant improvement in c-statistic estimate for NRM was observed after combining the HCT-CI with biomarkers in the validation set with patients from multiple institutions and varying practices.
This particular analysis had 2 limitations. First, the retrospective assignment of HCT-CI scores between the participating institutions could have been inconsistent. We believe the improvement in c-statistic could have been more profound if the data had been collected more consistently using newly published guidelines (www.hctci.org) [42] and, preferably, in a prospective fashion. Second, data from some centers were missing complete information for some of the biomarkers. Nevertheless, the robust overall sample size and our careful approach of defining associations in a training set and then validating findings in an independent cohort support generalization of the findings.
The mechanisms accounting for the association of low platelet counts and high ferritin and low albumin concentrations in the serum with prognosis after allogeneic HCT have not been defined. Nonetheless, the biomarkers identified in this large multicenter study warrant consideration together with the comorbidities captured by the HCT-CI when the fitness of patients for allogeneic HCT is evaluated. These laboratory values are readily obtained in the clinic, are easily interpreted, and can be used to provide prognostic information to patients and their families. Future studies should concentrate on determining whether specific interventions to improve these laboratory values before HCT will lead to reduced treatment-related mortality and improved OS.
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